摘要
AIM:Tocomparetheeffectivenessandsafetybetweenbevacizumabandranibizumabinthetreatmentofagerelatedmaculardegeneration(AMD)throughasystematicreviewandmeta-analysis.METHODS:Weperformedacomprehensivesearchofrandomizedcontrolledtrials(RCTs),non-RCTs,casecontrolandcohortstudiesthatcomparedbevacizumabandranibizumabusingPubMedandtheCochraneLibrary.Aftertherelateddatawereextractedbytwoinvestigatorsindependently,pooledweightedmeandifferences(WMDs)andriskratios(RRs)with95%confidenceintervals(CIs)wereestimatedusingarandom-effectsorafixed-effectsmodel.RESULTS:AtotaloffourRCTsinvolving1927patientsandelevenretrospectivecaseseriesinvolving2296patientswereincluded.Fortheprimaryoutcomes,nosignificantdifferenceswerefoundbetweenranibizumabgroupandbevacizumabgroupinvisualacuity(WMD:-0.04;95%CI:-0.08to0.00;P=0.06),bestcorrectedvisualacuity(WMD:-0.05;95%CI:-0.10to0.00;P=0.05),retinathickness(WMD:-4.69;95%CI:-13.15to3.76;P=0.86)andfovealthickness(WMD:10.91;95%CI:-14.73to36.56;P=0.40).Thepooledanalysesintheevaluationofsafetyshowedthatcomparedtobevacizumab,ranibizumabwasassociatedwithdecreasedrisksofocularinflammation(RR:0.45;95%CI:0.23to0.89;P=0.02)andvenousthromboticevents(RR:0.27;95%CI:0.08to0.89;P=0.03).However,therewerenosignificantdifferencesobservedindeaths(P=0.69)andarterialthromboembolicevents(P=0.71)betweenthetwogroups.CONCLUSION:Withequalclinicalefficacy,ranibizumabwasfoundtobeassociatedwithlessadverseeventscomparedtobevacizumab,indicatingthatranibizumabmightbeasafermanagement.
出版日期
2014年02月12日（中国期刊网平台首次上网日期，不代表论文的发表时间）
